4Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews, 2002, 6(2): 97-111.
5Daley M, Morin CM, LeBlanc M. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep, 2009, 32 (1): 55-64.
6Hajak G, Rodenbeck A, Voderholzer U. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001, 62(6): 453-463.
7Rodenbeck A, Cohrs S, Jordan W. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology (Berl), 2003, 170(4): 423-428.
8Roth T, Rogowski R, Hull S. Efficacy and safety of doxepin 1 mg, 3 rag, and 6 mg in adults with primary insomnia. Sleep, 2007, 30(11): 1555-1561.
9Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 rag, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry, 2008, 69(10): 1557-1564.
10Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www. cochranehandbook.org.
